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Hyperphosphatemia is an important consequence of chronic
renal failure (CRF). Lowering of the plasma phosphate
concentration is believed to be critical in the management of
patients with CRF, especially those on dialysis. Reports of the
effect of CRF on the intestinal handling of phosphate in vitro
have been conflicting; but what happens in vivo has not been
studied. What effect a reduction in the dietary phosphate
intake has on intestinal phosphate absorption in CRF in vivo
is unclear. In this study, we have used the in situ intestine
loop technique to determine intestinal phosphate absorption
in the 5/6-nephrectomy rat model of CRF under conditions of
normal and restricted dietary phosphate intake. In this model
of renal disease, we found that there is no significant change
in the phosphate absorption in either the duodenum or
jejunum regardless of the dietary phosphate intake. There
was also no change in the expression of the messenger
RNA of the major intestinal phosphate carrier the
sodium-dependent-IIb transporter. Furthermore, we found
no change in the intestinal villus length or in the location of
phosphate uptake along the villus. Our results indicate that
in CRF, unlike the kidney, there is no reduction in phosphate
transport across the small intestine. This makes intestinal
phosphate absorption a potential target in the prevention
and treatment of hyperphosphatemia.
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Phosphate homeostasis is largely a balance between intestinal
absorption and renal excretion of phosphate as well as an
internal contribution from bone. Phosphate balance is
influenced predominantly by three sodium-dependent phos-
phate transporters expressed in the brush border membrane
(BBM) of renal and intestinal epithelia. These transporters
are members of the solute carrier family SLC34 (www.
gene.ucl.ac.uk/nomenclature).1
In the kidney, the isoform NaPi-IIa, has been localized to
the proximal convoluted tubule, with its highest expression
in the S1 segment.2,3 Numerous studies have confirmed that
this protein is the major transporter involved in renal
phosphate reabsorption and that it possesses molecular
motifs responsible for its rapid regulation by endocytosis
and exocytosis.4,5 NaPi-IIc is also present at the BBM of the
proximal convoluted tubule; however, its expression level
depends on the age of the animal, with highest expression
during weaning, making it likely that it plays a more
important role in renal phosphate reabsorption during early
growth and development.6
In the small intestine, the isoform NaPi-IIb is considered
to be the rate-limiting step for phosphate absorption.1,7 Early
studies using in vitro preparations of rat small intestine
demonstrated that the duodenum and jejunum are respon-
sible for the bulk of intestinal phosphate absorption;8,9 more
recent studies in mice have shown that NaPi-IIb protein is
expressed in the ileum as well as in the proximal small
intestine.10,11 Our own work using in situ loops of rat small
intestine12 has confirmed earlier findings that phosphate
absorption occurs predominantly in the proximal small
intestine in this species.
Chronic renal failure (CRF) is almost always associated
with hyperphosphatemia, which can lead to secondary
hyperparathyroidism and vascular and soft tissue calcifica-
tion that has been linked to increased cardiovascular
morbidity and mortality.13,14 Normalization of plasma
phosphate levels is believed to be critically important in the
treatment of patients with CRF. Several studies have assessed
the role of the kidneys in maintaining a normal plasma
phosphate concentration in CRF and have demonstrated
an increase in fractional phosphate excretion owing to
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downregulation of NaPi-IIa (indicated by reduced messenger
RNA (mRNA) and protein expression). However, because the
number of functioning nephrons is reduced in CRF, this
adaptive decrease in renal phosphate reabsorption, and
increase in urinary phosphate excretion, is not sufficient to
prevent phosphate overload and hyperphosphatemia.15
There is less information on intestinal phosphate handling
in CRF. Studies using BBM vesicles prepared from the small
intestine of rats with experimentally induced CRF have
provided conflicting data, with phosphate uptake reported as
reduced16 or unchanged.17,18 However, the effect of experi-
mental CRF on phosphate transfer from lumen to blood has
not been examined. As attempts to reduce phosphate
absorption along the small intestine with phosphate bin-
ders14,19 and a low-phosphate diet are widely used to
minimize hyperphosphatemia in CRF, we investigated the
effects of CRF and dietary phosphate manipulation on
intestinal phosphate absorption in vivo in a rat model of CRF.
RESULTS
5/6-nephrectomy and a normal phosphate diet
Animals that had undergone a 5/6-nephrectomy showed a
significant reduction in body-weight gain compared with
sham-operated controls (Table 1) over the 5-week recovery
period. However, this represented less weight gain in the
week following surgical procedures, as during the 3 weeks
immediately before use for uptake experiments sham-
operated and 5/6-nephrectomized animals gained weight at
the same rate (results not shown). 5/6-nephrectomized
animals had reduced hematocrit and plasma 1,25-dihydroxy-
vitamin D3 levels and increased plasma concentrations of
urea, creatinine, parathyroid hormone (PTH), and phosphate
compared with sham-operated animals (Table 1). These
results confirm the induction of CRF.
The intestinal sodium-phosphate transporter protein,
NaPi-IIb, has been localized previously along the entire villus
length.20 However, using autoradiography our data show for
the first time that only those enterocytes located in the mid to
upper region of duodenal and jejunal villi are responsible for
phosphate uptake (Figure 1). CRF had no effect on the villus
profile for phosphate uptake and did not induce any change
in villus size in either the duodenum or jejunum (Table 2).
In sham-operated animals, phosphate absorption mea-
sured in vivo was higher in the duodenum than in the
jejunum at all time points of blood sampling (Figure 2). Over
the 30-min period, absorption was 192% greater in the
duodenum (Po0.01). A similar profile for absorption by the
two regions of small intestine was seen in animals that had
undergone a 5/6-nephrectomy. However, although absorp-
tion by the duodenum was higher at all points of blood
sampling, only at 30 min did this reach statistical significance
(Po0.05) (Figure 2). CRF had no effect on jejunal phosphate
absorption and although there was a trend towards a decrease
in absorption in the duodenum during CRF, this did not
Table 1 | Parameters confirming the induction of CRF: n=6–12 rats per experimental group, results are expressed as
mean7s.e.m.
Animal
weight gain (g)
Hematocrit
(%)
Plasma urea
(mg/dl)
Plasma
creatinine
(mg/dl)
Plasma
phosphate
(mg/dl)
1,25-
dihydroxyvitamin
D3
(pg/ml)
PTH
(pg/ml)
Sham 112.570.35 4570.34 18.972.9 0.3570.01 6.2370.02 127.5712.2 187712
5/6-nephrectomy 100.473.20* 4170.46*** 38.573.3** 0.8270.05* 7.7570.03** 40.0720.5** 403786*
5/6-nephrectomy+low-Pi diet 97.677.35 4270.88** 32.873.1* 0.8770.34* 7.9670.60* 276.279.97***,### 196716#
CRF, chronic renal failure; PTH, parathyroid hormone.
*Po0.05, **Po0.01, ***Po0.001 compared with sham and #Po0.05, ###Po0.001 compared with 5/6 nephrectomy using a one-way analysis of variance with post hoc
comparisons performed using the Bonferroni multiple comparisons test.
Sham duodenum Nephrectomy duodenum
Nephrectomy jejunumSham jejunum
Figure 1 | Autoradiography (left section) and light field (right section) images of duodenum and jejunum from sham and
5/6-nephrectomy animals (bar¼ 100 lm). Uptake was performed in vitro for 2 min using 100 mM 32P phosphate.
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reach statistical significance (Figure 2). Short-term in vitro
uptake studies designed to establish the degree of phosphate
retention by enterocytes in different regions of the small
intestine revealed that jejunal enterocytes of sham-operated
and 5/6-nephrectomized animals retained significantly great-
er levels of phosphate than those in the duodenum (Figure 3).
CRF did not produce any change in the degree of phosphate
retention in either region of the small intestine (Figure 3).
Real-time polymerase chain reaction (PCR) revealed a
significant decrease in expression of NaPi-IIa mRNA in
kidneys of CRF animals compared with sham-operated rats
(Po0.0001, Figure 4). In contrast, expression of duodenal or
jejunal NaPi-IIb mRNA was not significantly affected by CRF
(Figure 5).
5/6-nephrectomy and a low-phosphate diet
5/6-nephrectomized animals maintained on a low-phosphate
diet for 10 days gained weight at a similar rate to those
maintained on a normal diet (Table 1). Food intake was also
similar in the two groups (results not shown). In addition, a
reduction in dietary phosphate availability failed to cause any
change in hematocrit or plasma concentrations of creatinine
or urea in 5/6-nephrectomized animals (Table 1). In contrast,
hyperparathyroidism was prevented in 5/6-nephrectomized
animals that had been maintained on a low-phosphate diet
Table 2 | Villus length and width measurements in sham and
5/6-nephrectomy animals
Length (mm) Width (mm)
Sham – duodenum 0.3070.01 0.10370.004
5/6-nephrectomy – duodenum 0.3270.01 0.10470.003
Sham – jejunum 0.2670.01 0.09470.003
5/6-nephrectomy – jejunum 0.2870.02 0.09170.004
Results are expressed as mean7s.e.m. of six sections from different animals, from
which three villi were measured.
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Figure 2 | In vivo uptake of phosphate by the duodenum and
jejunum of sham-operated and 5/6-nephrectomized animals.
Results are expressed as mean7s.e.m. of six experiments per region
as a percentage of the initial counts transferred from 5 cm of small
intestine into 1 ml of blood. **Po0.01, compared with sham jejunum
and #Po0.05 compared with 5/6-nephrectomy jejunum using a
one-way analysis of variance with post hoc comparisons performed
using the Bonferroni multiple comparisons test.
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Figure 3 | Mucosal retention of phosphate in the duodenum and
jejunum of sham-operated and 5/6-nephrectomized animals.
Results are expressed as mean7s.e.m. of six experiments per region
in nmol/g mucosa. *Po0.05, **Po0.01 compared with duodenum
using a one-way analysis of variance with post hoc comparisons
performed using the Bonferroni multiple comparisons test.
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Figure 4 | Real-time PCR quantification of NaPi-IIa mRNA in the
kidney of sham and 5/6-nephrectomized rats. Results are
expressed as the mean7s.e.m. of duplicate PCR reactions performed
on six individual samples. The abundance of NaPi-IIa is given as a
ratio of NaPi-IIa mRNA to b-actin mRNA in arbitrary units (AU).
***Po0.001 using an unpaired t-test.
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Figure 5 | Real-time PCR quantification of NaPi-IIb mRNA in
the duodenum and jejunum of sham and 5/6-nephrectomized
rats. Results are expressed as the mean7s.e.m. of duplicate PCR
reactions performed on six individual samples. The abundance
of NaPi-IIb is given as a ratio of NaPi-IIb mRNA to b-actin mRNA in
arbitrary units (AU).
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(Po0.05), whereas 1,25-dihydroxyvitamin D3 levels were
significantly increased in these animals (Po0.001) (Table 1).
mRNA expression levels of NaPi-IIa were significantly
increased (Po0.01) in 5/6-nephrectomized animals main-
tained on a low-phosphate diet (Figure 6); however, this
adaptation, which has been reported to enhance renal
phosphate transport across the BBM,18 did not alter plasma
phosphate levels in these animals (Table 1).
In the intestine, reducing dietary phosphate availability in
CRF animals did not influence the rate of phosphate
absorption by the jejunum (Figure 7), a region that has
been shown previously to be highly responsive to vitamin
D.12 Gene expression of NaPi-IIb in both jejunum and
duodenum was also unaffected by low dietary phosphate
(Figure 8).
DISCUSSION
In this study, we have examined the effect of CRF on
intestinal phosphate absorption using the in situ intestinal
loop technique. Our results indicate that unlike the kidney,
intestinal phosphate absorption is unchanged when com-
pared with animals with normal renal function. Restricting
dietary phosphate availability in our model of CRF did
change the expression of the renal phosphate transporters,
but it had no effect on net intestinal phosphate absorption.
Our findings also demonstrate that there is no change in the
expression levels of the transcript for NaPi-IIb in either the
duodenum or jejunum in CRF, regardless of dietary
phosphate level. Unfortunately, there is no commercial
antibody against rat NaPi-IIb currently available, so we were
unable to compare our uptake and mRNA data with protein
expression for this transporter.
In mice, NaPi-IIb protein has been localized to the BBM of
enterocytes along the entire villus length.20 However, the
exact population of enterocytes responsible for phosphate
uptake along the rat villus has not been determined before.
Using autoradiography, we have shown that only those
enterocytes located in the mid to upper region of duodenal
and jejunal villi are responsible for phosphate uptake. This is
also true for the uptake of other luminal components, such as
glucose21 and iron,22 and (important in CRF) 1,25-dihydro-
xyvitamin D3-stimulated calcium transport;
23 and reflects the
time required for full expression of transport proteins during
enterocyte migration along the villus. Changes in intestinal
morphology and enterocyte maturation have the potential to
influence the rate of phosphate absorption in CRF. Previous
histological studies on small intestinal biopsies obtained from
patients with CRF have documented structural abnormalities
of the mucosa, including a reduction in villus length.24–26
However, consistent with our uptake data, we found no
change in villus size or the population of enterocytes
involved in phosphate uptake in the 5/6-nephrectomy model
of CRF.
Another mechanism by which intestinal absorption could
be modulated is by a change in its basolateral transport. Our
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Figure 6 | Real-time PCR quantification of NaPi-IIa mRNA in the
kidney of 5/6-nephrectomized rats maintained on a normal or
low-phosphate diet for 10 days. Results are expressed as the
mean7s.e.m. of duplicate PCR reactions performed on six individual
samples. The abundance of NaPi-IIa is given as a ratio of NaPi-IIa
mRNA to b-actin mRNA, in arbitrary units (AU). **Po0.01 using an
unpaired t-test.
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Figure 7 | In vivo uptake of phosphate by the jejunum of
5/6-nephrectomized animals maintained on a normal or a
low-phosphate diet for 10 days. Results are expressed as
mean7s.e.m. of six experiments as a percentage of the initial counts
transferred from 5 cm of small intestine into 1 ml of blood.
0
1
2
3
4
Duodenum Jejunum
R
at
io
 (A
U)
Normal diet
Low Pi diet
Figure 8 | Real-time PCR quantification of NaPi-IIb mRNA in the
duodenum and jejunum of 5/6-nephrectomized rats maintained
on a normal or low-phosphate diet for 10 days. Results are
expressed as the mean7s.e.m. of duplicate PCR reactions performed
on six individual samples. The abundance of NaPi-IIb is given as a
ratio of NaPi-IIb mRNA to b-actin mRNA in arbitrary units (AU).
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findings from short-term in vitro uptake studies (designed to
establish the degree of phosphate retention by enterocytes in
different regions of the small intestine) showed that jejunal
enterocytes retained significantly greater amounts of labeled
phosphate than those in the duodenum. CRF did not alter
the pattern or degree of phosphate retention in either region
of the small intestine, again indicating a lack of any effect of
CRF on net intestinal phosphate absorption. Interestingly,
the in vivo and in vitro findings from sham-operated animals
showed distinct differences in the handling of phosphate by
the two regions of the small intestine. Phosphate absorption
measured in vivo was significantly higher in duodenum than
jejunum; which may result from increased retention of
phosphate by jejunal enterocytes, because of a difference in
the basolateral exit pathway for phosphate. Overall, these
data suggest that per unit length the duodenum is capable of
absorbing a larger proportion of dietary phosphate than the
jejunum. However, because of the duodenum’s shorter length
and more rapid transit time,27 it is possible that the jejunum
is responsible for the bulk of dietary phosphate absorption
in vivo.
The finding that CRF reduces renal expression of NaPi-IIa,
but does not change phosphate absorption in the small
intestine may result from different mechanisms involved in
regulating phosphate transport. Plasma PTH concentration is
considered to be a major physiological regulator of renal
phosphate reabsorption, with high circulating PTH levels
stimulating rapid endocytosis of NaPi-IIa protein from the
proximal tubule BBM.28,29 As in earlier reports, animals that
had undergone a 5/6-nephrectomy showed signs of second-
ary hyperparathyroidism, with an increase in plasma PTH
and decrease in plasma 1,25-dihydroxyvitamin D3 levels.
30–32
Therefore, the reduction in renal NaPi-IIa expression during
CRF may be the result of increased circulating levels of PTH.
In contrast, though still controversial, the current view is that
PTH plays no direct role in the regulation of NaPi-IIb in the
small intestine,7,33,34 which is consistent with our finding of
no change in intestinal phosphate absorption in CRF.
A change in dietary phosphate is known to be a
physiological regulator of renal and intestinal phosphate
handling in several mammalian species, resulting in increased
expression and activity of NaPi-IIa and NaPi-IIb proteins,
respectively.1,35–38 Thus, restricting dietary phosphate levels
in CRF could increase phosphate transport in both tissues
and offset any tendency to a decrease in circulating
phosphate concentration. Early studies suggested that
changes induced by a low-phosphate diet depended on
stimulation of renal 25-hydroxyvitamin-D3-1a-hydroxylase,
leading to an increase in circulating levels of 1,25-dihydrox-
yvitamin D3
39,40 as well changes in expression of the vitamin
D receptor41 and calbindin.42 However, this mechanism has
been challenged recently, because upregulation of the
sodium-phosphate cotransporters in response to a restricted
dietary phosphate intake occurs in vitamin D receptor-null
mice and in 25-hydroxyvitamin-D3-1a-hydroxylase-deficient
mice.43,44 Moreover, our results show that feeding a low-
phosphate diet to rats with CRF does not influence the rate of
phosphate absorption measured in vivo or the mRNA
expression of NaPi-IIb, yet the circulating levels of 1,25-
dihydroxyvitamin D3 levels increased significantly. Our
observation of an increase in 1,25-dihydroxyvitamin D3
levels in phosphate-restricted 5/6-nephrectomized rats (in
contrast to the decrease observed without restriction) has
been noted previously31,45–47 and is further evidence that the
1,25-dihydroxyvitamin D3–vitamin D receptor axis seems not
to influence intestinal phosphate absorption in CRF.
Our finding that no change in intestinal phosphate
absorption in vivo following dietary phosphate restriction
in CRF is in contrast to reports using intestinal BBM
vesicles.18 This apparent discrepancy may reflect differences
in the phosphate content in the diet, the severity of renal
failure, the degree of hyperphosphatemia, or differences in
the techniques used in this and the previous studies.
However, the in vitro BBM technique measures potential
uptake at the apical membrane, whereas our in vivo loop
perfusion method records net transfer across the apical and
basolateral membranes, and is also dependent on any local
changes in vascular perfusion, and is perhaps more
physiological.
As reported previously, dietary phosphate restriction in
CRF leads to a reduction in circulating PTH levels,31,48–50
which is at least partially responsible for the increase in
mRNA levels of NaPi-IIa we found in our CRF rats on a low-
phosphate diet. However, this upregulation of NaPi-IIa had
no impact on plasma phosphate levels, probably because of
the reduced number of functioning nephrons. Indeed, it has
been suggested that in patients with CRF, adaptive changes in
the renal sodium-phosphate cotransporter may negate any
effect of dietary phosphate restriction on plasma phosphate
levels.51
Overall, our results demonstrate that in CRF the adaptive
response to dietary phosphate restriction is maintained by
the kidney, but that there is no change in the small intestine.
However, the mechanisms responsible for these differences in
phosphate handling during dietary phosphate restriction in
normal animals and those with CRF are still unclear. Several
recent studies have highlighted a role for fibroblast growth
factor (FGF)-23 in phosphate homeostasis (reviewed in
Fukagawa et al.52 and Imel and Econs53). It has been shown
to increase fractional phosphate excretion and decrease
plasma phosphate levels in mice54,55 by reducing NaPi-IIa
mRNA and protein levels.54 It has also been found to
decrease phosphate absorption in the mouse small intestine
by reducing the expression of NaPi-IIb.56 Changes in dietary
phosphate can regulate FGF-23. High-phosphate diets
increase circulating levels, whereas dietary phosphate
restriction decreases them.57,58 Interestingly, circulating
FGF-23 levels also increase as renal function declines in
rodents and patients with CRF.59,60 There is some evidence
that although the response of FGF-23 to dietary phosphate
restriction is maintained in animals with CRF, levels of this
phosphatonin are significantly higher in 5/6-nephrectomized
170 Kidney International (2007) 72, 166–173
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animals fed a low-phosphate diet compared with sham-
operated animals fed a normal rat chow.60 In addition, the
vitamin D metabolite 24,25-dihydroxyvitamin D3 has been
shown to have effects opposite to those of 1,25-dihydrox-
yvitamin D3. It downregulates calcium absorption,
61 possibly
through an effect on the small intestine.62 This metabolite has
also been shown to inhibit 1,25-dihydroxyvitamin D3-
induced stimulation of phosphate transport in renal and
intestinal cells in vitro.63,64 Whether these or other phospha-
tonin-like factors are involved in blunting the response of the
small intestine to dietary phosphate restriction in CRF
requires further study.
Phosphate binders and dietary phosphate restriction are
widely used to control hyperphosphatemia in CRF. However,
maintaining a low-phosphate diet is difficult and can result in
malnutrition13 and none of the currently available binders is
ideal.13,14,19,65 An alternative approach is to directly target the
renal and/or intestinal sodium-dependent phosphate cotran-
sporters. Both competitive and noncompetitive inhibitors
have been studied and show promising phosphaturic effects
and an ability to reduce hyperphosphatemia,15–17,66,67 but
this is of limited benefit when there is little or no residual
renal function. Perhaps a more physiological approach is to
explore the use of phosphatonins like recombinant FGF-23,52
which may inhibit renal and intestinal phosphate transport.
The in situ isolated intestinal loop technique could be a
method of establishing their effectiveness and mode of action
in vivo.
In conclusion, our findings demonstrate that unlike the
kidney, there is no intrinsic change in intestinal phosphate
handling in vivo in the 5/6-nephrectomy model of CRF.
Moreover, in this setting, restricting dietary phosphate does
not reduce plasma phosphate levels. Importantly, the fact that
intestinal handling of phosphate is not altered (down-
regulated) in CRF makes it a more suitable therapeutic
target in the management of hyperphosphatemia.
MATERIALS AND METHODS
Animals and surgical protocol for the induction of CRF
Male Sprague–Dawley rats (230 g) bred at the Royal Free
Comparative Biology Unit underwent a two-stage, 5/6-nephrectomy
or sham operation. Under halothane anesthesia (2–3% halothane in
100% oxygen) the left kidney was exposed via a mid-line incision
and the renal capsule removed. The renal pedicle was temporarily
clamped and 7/8 of the cortex resected (equivalent to B2/3 of the
single kidney mass). The remnant kidney was then wrapped in
Surgicel (Ethicon Inc., Livingston, UK) and the clamp removed. The
abdominal incision was then closed and a subcutaneous injection of
Rimadyl& (5 mg/kg subcutaneously, Pfizer Ltd, Kent, UK) was given
immediately after surgery and after 6 h. One week later, again under
halothane anesthesia, the right kidney was removed via a flank
incision and the same recovery procedure employed. For the sham
operation, the same procedures were carried out except the kidney
was gently manipulated rather than being partially resected or
removed. After surgery, animals were allowed ad libitum access to
water and a standard rat chow containing 0.52% phosphorous,
0.73% calcium, and 0.62 IU/g vitamin D (Diet RM1, SDS Ltd,
Witham, Essex, UK). Subsets of nephrectomized animals were fed a
low-phosphate diet containing 0.02% phosphorous, 0.6% calcium,
and 0.4 IU/g vitamin D for 10 days (Harlan Tekland, Indianapolis,
IN). All procedures were carried out in accordance with the Animals
(Scientific Procedures) Act 1986.
In vivo experiments
Four weeks after the second surgical procedure, animals were
anesthetized with an intraperitoneal injection of 60 mg/kg pento-
barbitone sodium (Pentoject, Animalcare Ltd, York, UK) and
maintained at 371C using a thermostatically controlled heating
blanket (Harvard Apparatus Ltd, Kent, UK). The femoral artery was
cannulated for removal of blood samples. Five-centimeter long
segments of duodenum (first 5 cm from stomach) or jejunum (5 cm
from the ligament of Tritz) were cannulated and flushed with warm
0.9% saline, followed by air. Uptake buffer (500 ml) containing
(mmol/l) 16 Na–N-2-hydroxyethylpiperazine-N0-2-ethanesulfonic
acid, 140 NaCl, 3.5 KCl, 0.1 KH2PO4, and approximately 1.5 MBq
32Pi (PerkinElmer, Bucks, UK) was instilled in the lumen and the
segment tied off. Blood (0.5 ml) was collected at 5, 10, 15, and
30 min intervals and centrifuged at high speed for 15 min to obtain
plasma. The segment of small intestine was removed and washed
with 0.9% saline, blotted, and the segment length and wet weight
recorded. Scintillation counting of the plasma and initial uptake
solution permitted calculation of phosphate transfer from the lumen
in 1 ml of blood, by 5 cm of small intestine. At the end of the
experiment, blood was collected for measurement of hematocrit and
plasma obtained by centrifugation at high speed for 15 min. Assay
kits for plasma urea, creatinine (Thermotrace Ltd, Melbourne,
Australia), phosphate (Universal Biologicals, Cambridge, UK), rat
bioactive intact PTH, and 1,25 dihydroxyvitamin D3 (Immuno-
diagnostics, Bolton, UK) were used according to the respective
manufacturer’s instructions.
In vitro uptake experiments
Segments of duodenum and jejunum (5 cm) were removed from
sham-operated or 5/6-nephrectomized animals anesthetized with
pentobarbitone sodium (60 mg/kg intraperitonealy), flushed with
ice-cold 0.9% saline and everted on glass rods. Samples were
securely mounted on the rod and then preincubated for 5 min at
371C in oxygenated buffer, pH 7  4, containing in mM: hydro-
xyethylpiperazine-N0-2-ethanesulfonic acid 16, glucose 10, KCl 3  5,
MgSO4 10, CaCl2 1, NaCl 125, followed by 2 min incubation in the
same buffer containing 100mM 32Pi (32Pi-specific activity 1.85 MBq/
ml). The buffer was rapidly stirred using a magnetic flea to minimize
the effects of static water layers at the mucosal surface. Uptake was
terminated by exposing the tissue for 10 min at room temperature to
phosphate-buffered saline containing a 10-fold excess of nonra-
dioactive phosphate. This procedure was followed by a further
10 min wash in phosphate-buffered saline at room temperature and
samples were then blotted dry and the weight recorded. Samples
were digested overnight in Protosol (PerkinElmer). Scintillation
counting of the digested sample and initial uptake solution
permitted calculation of phosphate retention of tissue (in nmol/g).
Real-time PCR
Kidneys or segments of duodenum and jejunum (5 cm) were
removed from sham and 5/6-nephrectomized animals anesthetized
with pentobarbitone sodium (60 mg/kg intraperitonealy). Small
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intestine samples were flushed with ice-cold 0.9% saline and the
mucosa scraped using glass slides. Kidneys or mucosal scrapes were
then snap-frozen in liquid nitrogen and stored at 801C until use.
Total RNA was extracted from kidneys or mucosal scrapes using a
QIAamp RNA blood mini kit according to the manufacturer’s
instructions (Qiagen, West Sussex, UK). RNA was reverse trans-
cribed with 0.5 mg of oligo-dT 12–18 primer and a first strand cDNA
synthesis kit (Superscript II RNase H reverse transcriptase; Life
Technologies, Scotland, UK). NaPi-IIa and NaPi-IIb transporter
transcripts were analyzed by real-time PCR using QuantiTech
SYBRs Green PCR kit (Qiagen) on a LightCycler real-time PCR
instrument (version 3.5; Roche Diagnostics, East Sussex, UK) using
specific primers designed from the published sequence of the rat
NaPi-IIa transporter (accession number NM013030; forward
position 951–969, reverse position 1315–1300) and mouse NaPi-
IIb transporter (accession number AF081499; forward position
1402–1418, reverse position 1631–1616). The levels of b-actin
transcripts were assessed in parallel experiments using primers
designed from the sequence of rat b-actin (accession number
NM031144; forward position 937–955, reverse position 1223–1208).
For all primers, cycling conditions were as follows: 951C for 10 min
followed by 45 cycles of 951C for 15 s, 601C for 20 s, and 721C for
40 s with transition rates of 201C/sec and a single fluorescence
acquisition at 811C. A standard curve for each gene was established
by performing the above procedure with serially diluted DNA
samples of known concentrations. The relative amounts of the
target and reference genes in each sample were then calculated
based on the crossing-point analysis (Relquant, version 1.01; Roche
Diagnostics); the second derivative maximum method was used
to automatically determine the crossing point for individual
samples.
Autoradiography, histology, and villus size measurements
Segments of duodenum and jejunum (5 cm) were removed from
sham and 5/6-nephrectomized animals anesthetized with pentobar-
bitone sodium (60 mg/kg intraperitonealy), flushed with ice-cold
0.9% saline and everted on glass rods. For autoradiography,
phosphate uptake was carried out using the same protocol as the
in vitro uptake experiments. However, following the final 10 min
wash in phosphate-buffered saline, samples were fixed in glutar-
aldehyde (2% v/v) for 2 h, followed by overnight fixation in
formaldehyde–saline (4% v/v). Samples were then dehydrated,
cleared, and embedded in wax and sectioned (7mm) using a sledge
microtome (Anglian Scientific, Cambridge, UK). Sections were
mounted onto grease-free, gelatin/chrome alum-subbed slides,
baked, dewaxed, exposed to K2 photographic emulsion (IIford
Imaging UK Ltd, Cheshire, UK), and incubated in the dark for 7–14
days. Slides were then developed in D19 (Kodak Ltd, Hertfordshire,
UK), stopped and fixed using Hypam photographic fixative (IIford
Imaging UK Ltd). Sections were then counterstained with light
green stain, dehydrated, cover-slipped, and photographed in dark
field using a Nikon Coolpix 4500 digital camera attached to an
Olympus Vanox microscope. Consecutive sections were stained with
hematoxylin and eosin to allow measurement of villus length and
width using a projecting microscope (Gillett & Sibert Ltd, Glasgow,
UK) fitted with a graticule.
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